Cite
HARVARD Citation
Quach, H. et al. (2021). Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British journal of haematology. pp. 784-788. [Online].